TRAIL (DR5) receptor and the modulation of TRAIL pathway in PLWHIV: key mechanisms in the progression of HIV disease
Sarah Ratkovich-González(Universidad de Guadalajara), Karina Sánchez-Reyes(Universidad de Guadalajara), Pedro Martínez-Ayala(Hospital Civil de Guadalajara), Jaime Andrade‐Villanueva(Hospital Civil de Guadalajara), Judith Carolina De Arcos-Jiménez(Universidad de Guadalajara), Monserrat Álvarez-Zavala(Universidad de Guadalajara), Mariana del Rocío Ruiz-Briseño(Universidad de Guadalajara), Vida Verónica Ruíz-Herrera(Hospital Civil de Guadalajara), Luz Alicia González-Hernández(Universidad de Guadalajara)
Cited by 0
Related Papers
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
|The Lancet Respiratory Medicine|2021|225
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
|The Lancet Infectious Diseases|2011|172
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
|Science Translational Medicine|2017|169
Oral Manifestations Associated with HIV/AIDS Patients
|Medicina|2022|97